This document discusses the detection and monitoring of adverse drug reactions (ADRs). It outlines that ADRs are detected through pre-marketing studies such as acute toxicity and specific animal tests as well as clinical trials. Post-marketing surveillance also plays an important role in ADR detection through spontaneous reporting systems and epidemiological methods. In hospitals, healthcare professionals can detect ADRs by closely monitoring high-risk patients and collecting detailed patient data to assess causality and severity of suspected ADRs.